Table 2 Summary baseline characteristic of reported case reports/series

Age

55.56 ± 19.70

41.66 ± 20.10

35.20 ± 15.51

60.38 ± 12.38

46.50 ± 9.19

Gender

 Male

53

10

2

8

1

 Female

47

4

3

5

1

Comorbidities

 HTN

18

3

0

1

0

 Dyslipidemia

8

0

0

0

0

 DM

12

0

0

1

0

 Heart disease

5

2

1

5

0

 Herpetic keratitis

0

2

0

0

0

 HIV

1

0

0

1

0

Immune status

 Immunocompetent

98

12

4

3

2

 Immunocompromised

2

0

1

10

0

Vaccine type

 Pfizer

54

7

2

8

0

 Moderna

7

0

0

3

1

 AstraZeneca

20

2

1

1

1

 Others

19

5

2

1

0

Vaccine dose

 1st

86

7

5

11

1

 2nd

12

2

0

2

1

 3rd (Booster)

2

1

0

0

0

Diagnosis

 PCR

34

3

2

13

0

 Clinical examination

63

8

3

0

2

 Immunoglobulin

2

0

0

0

0

Treatment

 Antiviral

52

2

0

11

0

 Pharmacological

5

2

2

0

2

 Both

30

10

0

1

0

Clinical manifestation

 Uncomplicated infections

95

14

5

13

2

 Serious infections

5

0

0

0

0